Depomed (NASDAQ:DEPO) is scheduled to be releasing its earnings data after the market closes on Monday, February 19th. Analysts expect Depomed to post earnings of $0.12 per share for the quarter.
Depomed (DEPO) opened at $6.46 on Monday. The company has a market cap of $407.06, a PE ratio of -3.53 and a beta of 1.07. The company has a quick ratio of 0.79, a current ratio of 0.83 and a debt-to-equity ratio of 2.90. Depomed has a fifty-two week low of $4.31 and a fifty-two week high of $17.86.
A number of research firms have recently commented on DEPO. Royal Bank of Canada set a $9.00 target price on shares of Depomed and gave the stock a “hold” rating in a report on Thursday, December 7th. Piper Jaffray Companies reissued a “hold” rating and issued a $9.00 target price on shares of Depomed in a report on Thursday, December 7th. BidaskClub cut shares of Depomed from a “hold” rating to a “sell” rating in a report on Tuesday, January 23rd. ValuEngine raised shares of Depomed from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 5th. Finally, Mizuho raised shares of Depomed from a “neutral” rating to a “buy” rating and set a $9.00 target price for the company in a report on Tuesday, December 5th. Three analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $11.64.
TRADEMARK VIOLATION WARNING: “Depomed (DEPO) to Release Earnings on Monday” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/12/depomed-depo-to-release-earnings-on-monday.html.
Depomed Company Profile
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.